Matches in SemOpenAlex for { <https://semopenalex.org/work/W2275794938> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2275794938 abstract "10574 Background: Neoadjuvant (primary) chemotherapy as part of multimodality treatment is increasingly used as standard of care for patients (pts) with locally advanced breast cancer and firmly established. We conducted a prospective study using doxorubicin 75 mg/m 2 q 3 weeks × 3 cycles followed sequentially by docetaxel 75 mg /m 2 and cisplatin 75 mg/m 2 q 3 weeks × 3cycles. All pts had definitive surgery followed by radiation therapy, ± tamoxifen. Primary end points were pathologic complete response (pCR), secondary endpoints were, safety, rate of conservative surgery and overall survival. Material: Eligible pts included biopsy proven invasive breast cancer, T2-T4 (primary = 4–10 cm) N0-N2, M0. 59 of 60 enrolled pts completed treatment one patient refused surgery after the completion of 6 cycles of chemotherapy were excluded from the analysis, median age:41yrs (24- 60), Premenopausal: 68%, median tumor size: 6.0cm (4 - 10), Stage IIB:32% and IIIA / IIIB: 68%, both ER / PR positive: 53%, Her2/neu (3+) by IHC staining and /or Fish positive: 29%. All patients had negative metastatic workup. Results: 59 pts are evaluable for analysis: clinical complete response was seen in: 44%, clinical partial response in: 56 %. Breast conserving surgery was performed in: 44 %, and MRM in: 56%. Pathological complete response (pCR) in the breast was: 31 %, in axilla were: 37 %. Grade3–4 Toxicities: Febrile Neutropenia: (13%), Nausea vomiting: (12%), Mucositis: (10%), weakness/asthenia/weight loss: 12%. Overall at follow up of 60 months the DFS & OS (67% and 74%).Patients who achieved complete pathologic response in breast and/or axilla the DFS and OS were (91%), 13 patients relapsed 46% were Her2 positive. Conclusion: Sequential combination of doxorubicin followed by docetaxel/cisplatin is a safe, feasible and active combination, that offer the possibility of conservative surgery and associated with high clinical and pathologic response, further investigation of this combinations are warranted. No significant financial relationships to disclose." @default.
- W2275794938 created "2016-06-24" @default.
- W2275794938 creator A5023233912 @default.
- W2275794938 creator A5042393350 @default.
- W2275794938 creator A5043632612 @default.
- W2275794938 creator A5054662738 @default.
- W2275794938 creator A5056517018 @default.
- W2275794938 creator A5066226581 @default.
- W2275794938 creator A5074062351 @default.
- W2275794938 creator A5076573965 @default.
- W2275794938 creator A5079530585 @default.
- W2275794938 date "2007-06-20" @default.
- W2275794938 modified "2023-09-27" @default.
- W2275794938 title "Prospective phase II study of neo-adjuvant doxorubicin followed by cisplatin /docetaxel in locally advanced breast cancer—5 years of follow up" @default.
- W2275794938 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.10574" @default.
- W2275794938 hasPublicationYear "2007" @default.
- W2275794938 type Work @default.
- W2275794938 sameAs 2275794938 @default.
- W2275794938 citedByCount "0" @default.
- W2275794938 crossrefType "journal-article" @default.
- W2275794938 hasAuthorship W2275794938A5023233912 @default.
- W2275794938 hasAuthorship W2275794938A5042393350 @default.
- W2275794938 hasAuthorship W2275794938A5043632612 @default.
- W2275794938 hasAuthorship W2275794938A5054662738 @default.
- W2275794938 hasAuthorship W2275794938A5056517018 @default.
- W2275794938 hasAuthorship W2275794938A5066226581 @default.
- W2275794938 hasAuthorship W2275794938A5074062351 @default.
- W2275794938 hasAuthorship W2275794938A5076573965 @default.
- W2275794938 hasAuthorship W2275794938A5079530585 @default.
- W2275794938 hasConcept C121608353 @default.
- W2275794938 hasConcept C126322002 @default.
- W2275794938 hasConcept C143998085 @default.
- W2275794938 hasConcept C2776694085 @default.
- W2275794938 hasConcept C2777863537 @default.
- W2275794938 hasConcept C2778239845 @default.
- W2275794938 hasConcept C2781190966 @default.
- W2275794938 hasConcept C2781303535 @default.
- W2275794938 hasConcept C31760486 @default.
- W2275794938 hasConcept C530470458 @default.
- W2275794938 hasConcept C71924100 @default.
- W2275794938 hasConceptScore W2275794938C121608353 @default.
- W2275794938 hasConceptScore W2275794938C126322002 @default.
- W2275794938 hasConceptScore W2275794938C143998085 @default.
- W2275794938 hasConceptScore W2275794938C2776694085 @default.
- W2275794938 hasConceptScore W2275794938C2777863537 @default.
- W2275794938 hasConceptScore W2275794938C2778239845 @default.
- W2275794938 hasConceptScore W2275794938C2781190966 @default.
- W2275794938 hasConceptScore W2275794938C2781303535 @default.
- W2275794938 hasConceptScore W2275794938C31760486 @default.
- W2275794938 hasConceptScore W2275794938C530470458 @default.
- W2275794938 hasConceptScore W2275794938C71924100 @default.
- W2275794938 hasLocation W22757949381 @default.
- W2275794938 hasOpenAccess W2275794938 @default.
- W2275794938 hasPrimaryLocation W22757949381 @default.
- W2275794938 hasRelatedWork W1606129292 @default.
- W2275794938 hasRelatedWork W1973241390 @default.
- W2275794938 hasRelatedWork W1991102770 @default.
- W2275794938 hasRelatedWork W1998091677 @default.
- W2275794938 hasRelatedWork W2005735799 @default.
- W2275794938 hasRelatedWork W2024961744 @default.
- W2275794938 hasRelatedWork W2040807345 @default.
- W2275794938 hasRelatedWork W2079108740 @default.
- W2275794938 hasRelatedWork W2162387248 @default.
- W2275794938 hasRelatedWork W3046680084 @default.
- W2275794938 isParatext "false" @default.
- W2275794938 isRetracted "false" @default.
- W2275794938 magId "2275794938" @default.
- W2275794938 workType "article" @default.